Literature DB >> 21638520

Safety surveillance of longitudinal databases: methodological considerations.

G Niklas Norén1, Johan Hopstadius, Andrew Bate, I Ralph Edwards.   

Abstract

Mesh：

Year:  2011        PMID： 21638520     DOI： 10.1002/pds.2151

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  9 in total

1.  Terminological challenges in safety surveillance.

Authors:  Andrew Bate; Elliot G Brown; Stephen A Goldman; Manfred Hauben
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection.

Authors:  Vaishali K Patadia; Martijn J Schuemie; Preciosa Coloma; Ron Herings; Johan van der Lei; Sabine Straus; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Int J Clin Pharm       Date:  2014-12-09

3.  A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance.

Authors:  Yihua Xu; Xiaofeng Zhou; Brandon T Suehs; Abraham G Hartzema; Michael G Kahn; Yola Moride; Brian C Sauer; Qing Liu; Keran Moll; Margaret K Pasquale; Vinit P Nair; Andrew Bate
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

Review 4.  Novel data-mining methodologies for adverse drug event discovery and analysis.

Authors:  R Harpaz; W DuMouchel; N H Shah; D Madigan; P Ryan; C Friedman
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

5.  A data-driven pipeline to extract potential adverse drug reactions through prescription, procedures and medical diagnoses analysis: application to a cohort study of 2,010 patients taking hydroxychloroquine with an 11-year follow-up.

Authors:  P Sabatier; M Wack; J Pouchot; N Danchin; A S Jannot
Journal:  BMC Med Res Methodol       Date:  2022-06-08       Impact factor: 4.612

6.  Statistical Power for Postlicensure Medical Product Safety Data Mining.

Authors:  Judith C Maro; Michael D Nguyen; Inna Dashevsky; Meghan A Baker; Martin Kulldorff
Journal:  EGEMS (Wash DC)       Date:  2017-06-12

7.  Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic.

Authors:  Jeffrey S Brown; Kenneth R Petronis; Andrew Bate; Fang Zhang; Inna Dashevsky; Martin Kulldorff; Taliser R Avery; Robert L Davis; K Arnold Chan; Susan E Andrade; Denise Boudreau; Margaret J Gunter; Lisa Herrinton; Pamala A Pawloski; Marsha A Raebel; Douglas Roblin; David Smith; Robert Reynolds
Journal:  Pharmaceutics       Date:  2013-03-14       Impact factor: 6.321

8.  Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.

Authors:  Anjan K Banerjee; Sally Okun; I Ralph Edwards; Paul Wicks; Meredith Y Smith; Stephen J Mayall; Bruno Flamion; Charles Cleeland; Ethan Basch
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

9.  Good Signal Detection Practices: Evidence from IMI PROTECT.

Authors:  Antoni F Z Wisniewski; Andrew Bate; Cedric Bousquet; Andreas Brueckner; Gianmario Candore; Kristina Juhlin; Miguel A Macia-Martinez; Katrin Manlik; Naashika Quarcoo; Suzie Seabroke; Jim Slattery; Harry Southworth; Bharat Thakrar; Phil Tregunno; Lionel Van Holle; Michael Kayser; G Niklas Norén
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.